Yttrium-90 radioembolization for unresectable neuroendocrine tumor liver metastases
10.3760/cma.j.issn.1007-8118.2016.05.020
- VernacularTitle:钇90微球栓塞治疗不可切除的神经内分泌肿瘤肝转移
- Author:
Shaoqin LI
;
Xiaocheng GU
;
Zhongzhi JIA
- Publication Type:Journal Article
- Keywords:
Neuroendocrine tumor;
Liver metastases;
Yttrium-90;
Radioembolization
- From:
Chinese Journal of Hepatobiliary Surgery
2016;22(5):355-357
- CountryChina
- Language:Chinese
-
Abstract:
Neuroendocrine tumor liver metastases (NETLM) is a uncommon advanced tumor disease.Patients with unresectable NETLM have a poor outcome.The management of unresectable NETLM is a clinical dilemma.However,Yttrium-90 radioembolization is a safe and effective treatment for NETLM patients.The median disease control rate is 87.1％ (64.7％ ～ 100％);the median overall survival time is 34.4 months;and the median overall survival rate of 1,2,and 3 years are 79.8％ (63％～100％),62％ (57％ ～62.5％),45.5％ (45％ ～ 46％),respectively.Although there is good result of Yttrium-90 radioembolization in treatment of unresectable NETLM,the safety and effectiveness should be further verified.
